Alto Neuroscience, Inc. (NYSE:ANRO – Free Report) – Equities research analysts at William Blair lowered their FY2028 earnings per share estimates for Alto Neuroscience in a research note issued to investors on Tuesday, October 22nd. William Blair analyst M. Minter now anticipates that the company will earn ($3.26) per share for the year, down from their prior forecast of ($3.16). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.63) per share.
Alto Neuroscience (NYSE:ANRO – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.07.
Read Our Latest Report on ANRO
Alto Neuroscience Price Performance
NYSE ANRO opened at $4.36 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 19.85 and a quick ratio of 19.85. The company has a 50 day simple moving average of $12.02 and a 200-day simple moving average of $12.36. Alto Neuroscience has a 52-week low of $3.93 and a 52-week high of $24.00.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers bought a new stake in Alto Neuroscience during the second quarter worth approximately $113,000. Federated Hermes Inc. grew its stake in Alto Neuroscience by 33.3% in the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock valued at $128,000 after buying an additional 3,000 shares during the last quarter. University of Texas Texas AM Investment Managment Co. bought a new position in Alto Neuroscience in the 1st quarter worth $340,000. Bank of New York Mellon Corp acquired a new position in Alto Neuroscience during the 2nd quarter worth $252,000. Finally, Bowie Capital Management LLC bought a new stake in Alto Neuroscience during the second quarter valued at about $462,000.
About Alto Neuroscience
Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
Further Reading
- Five stocks we like better than Alto Neuroscience
- How to Use the MarketBeat Stock Screener
- Texas Roadhouse Stock Steering for New Highs This Year
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Insider Trades May Not Tell You What You Think
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.